WALTHAM, MA / ACCESSIRE / September 19, 2022 / TRIANA Biomedicines, Inc. (TRIANA), an innovative biopharmaceutical company focused on building a target-first and rational molecular glue discovery platform for inactivating difficult to address disease targets, today announced that Dr. Patrick Trojer, President and Chief Executive Officer, will present at UBS Virtual Biotechnology Private Company Symposium on Thursday September 22, 2022 at 4:00 PM ET.
About TRIANA Biomedicines Inc
TRIANA Biomedicines is a private biotechnology company, headquartered in Waltham, Massachusetts and focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art AI and computational tools, and bespoke chemical libraries. TRIANA’s target-first and rational approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact
[email protected]
SOURCE: TRIANA Biomedicines, Inc.
View source version on accesswire.com:
https://www.accesswire.com/716350/TRIANA-Biomedicines-Announces-Participation-in-Upcoming-Investor-Conference